From "buy, buy" to "sell", pharmaceutical companies are accelerating their focus on the main business

"Pharmaceutical network industry dynamics" time to September, the current listed pharmaceutical companies half-yearly report has been all published.
, pharmaceutical companies are growing and declining in the first half of 2020, basically a 1:1 situation.
industry believes that if the first half is compared to the first half of the football match, basically reached a draw, the second half, as the impact of the outbreak becomes smaller, there is a good chance that the first half will be better.
From "buy and buy" to "sell and sell", pharmaceutical companies began to accelerate the focus on the main industry in addition, it is worth noting that from the semi-annual report of pharmaceutical companies can be clearly found that this year, there are a number of well-known pharmaceutical companies all started to sell assets.
to this, industry insiders said that pharmaceutical companies have sold assets, mainly to in-live assets, optimize the allocation of resources, focus on core business, control operational risks, while improving their own financial situation, thicken corporate profits, optimize financial statements.
As recently disclosed in the semi-annual report issued by People's Fu Pharmaceuticals, in order to divest non-core pharmaceutical assets, continue to optimize the business, capital structure, and to achieve business focus, 362 million sold another holding subsidiary of Sichuan People's Fu 70% of the shares.
In fact, since 2018, in order to improve the operational efficiency and risk resistance of assets, the pharmaceutical industry has begun to firmly implement the "naturalization" strategy, actively promote business focus and asset optimization, and decided to gradually withdraw from medical services and other areas with less obvious competitive advantages or weak synergies.
similarly, in its previously disclosed 2020 half-yearly report, Tiansli also showed that, in order to meet the strategic development needs of listed companies and enhance the sustainable development capabilities and core competitiveness of listed companies, on June 12, Tiansli and six partners indirectly controlled by Tiansli sold its stake in Tianjin Tiansli Pharmaceutical Marketing Group Co., Ltd. (99.9448%) to Chongqing Pharmaceutical (Group) Co., Ltd.
among them, the listed company Tiansli intends to sell 88.4937 percent of Tians Marketing to Chongqing Pharmaceuticals, and six partnerships indirectly controlled by the listed company intend to sell their combined 11.4511 percent stake in Tiansi Marketing to Chongqing Pharmaceuticals.
Addition, the semi-annual report industry recently released by Dong'a Gum shows that, in order to "slim down", Dong'a Gum has transferred its 25% stake in China Resources Onde Biopharmaceutical Co., Ltd. to China Resources Biopharmaceuticals.
that this is the first transfer of subsidiary shares since the "go-stocking" of Dong'a Gum.
In addition to the above-mentioned enterprises, Haizheng Pharmaceuticals, Haier Bio, Four Rings Biology, China Resources 39, Foci Pharmaceuticals and many other well-known pharmaceutical companies have also issued a number of asset sales announcements, mainly related to equity, land, real estate and so on.
overall, against the background of the long-term trend of health care fee control, the shift of pharmaceutical companies from the previous "buy and buy" to "sell and sell" will help pharmaceutical companies to accelerate their focus on the main industry and gain further development.
But it should be noted that in the face of policy changes in the future, pharmaceutical companies should also practice "internal skills", focus on their own advantages and resources in the field, through solid and effective research and development input, technological innovation, structural optimization, to obtain more profits and smoother capital flow, to provide support for sustainable development of enterprises;